



National HealthCare Corp. (NHC)

Updated August 14th, 2025, by Ian Bezek

Key Metrics

Current Price:	\$106	5 Year CAGR Estimate:	9.4%	Market Cap:	\$1.7 B
Fair Value Price:	\$113	5 Year Growth Estimate:	6.0%	Ex-Dividend Date:	09/30/25
% Fair Value:	94%	5 Year Valuation Multiple Estimate:	1.3%	Dividend Payment Date:	10/31/25
Dividend Yield:	2.4%	5 Year Price Target	\$151	Years Of Dividend Growth:	4
Dividend Risk Score:	D	Sector:	Real Estate	Rating:	Hold

Overview & Current Events

National HealthCare was founded in 1971 to own and manage medical facilities. It operates skilled nursing facilities, home and hospice agencies, assisted living facilities, independent living facilities, and behavioral health hospitals. Besides operating its own facilities, National HealthCare leases some facilities to third-party operators. As of June 30th, 2025, National Healthcare operated or managed 80 skilled nursing facilities with 10,329 licensed beds in addition to its assortment of other healthcare, homecare, and hospice assets.

National HealthCare was traditionally a stable business with predictable growth. The pandemic upended this, however. Earnings plunged in 2020, soared in 2021 thanks to government relief payments, and then plunged again in 2022 as the payments wound down. Industry conditions have finally stabilized now. Meanwhile, National HealthCare has adjusted its portfolio a bit to reflect the changing healthcare marketplace; it exited several Northeastern markets in 2022 to redouble its focus on its core Southern U.S. market. On August 1st, 2024, National HealthCare acquired White Oak, which added 15 skilled nursing facilities, two assisted living facilities, and four independent living facilities to its portfolio.

National HealthCare reported its Q2 results on August 8th, 2025. Adjusted earnings-per-share of \$1.52 soared from the \$1.00 figure recorded in the same period of 2024. Net patient revenues increased 30% to \$363 million for the quarter. The firm's operating results improved as pandemic-related headwinds have finally subsided, and the White Oak acquisition immediately contributed significantly to both the company's top- and bottom-line results. While the first half of the year has been excellent, we expect growth to begin to taper off in future quarters.

Growth on a Per-Share Basis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
EPS	\$3.20	\$3.32	\$3.69	\$3.87	\$4.44	\$2.72	\$5.32	\$2.42	\$3.55	\$4.93	\$5.65	\$7.56
DPS	\$1.48	\$1.75	\$1.89	\$1.98	\$2.06	\$2.08	\$2.08	\$2.26	\$2.34	\$2.42	\$2.56	\$3.27
Shares¹	15	16	15	15	15	15	15	15	15	15	15	15

National HealthCare had a generally increasing earnings-per-share trend over the past decade; at least that was the case until March 2020. With the onset of the pandemic, however, the business faced many additional costs for keeping facilities safe and well-staffed with qualified healthcare professionals, but it received government funding to offset this.

As this emergency aid wound down, however, the company's earnings slumped in 2022. 2023 was a return to form, though, and 2024 delivered excellent results. We are concerned about potential efforts to reduce government spending for the health care system, and higher labor costs are another potential headwind. And NHC's master lease with National Health Investors to use its properties ends in 2026, which could lead to a large increase in occupancy costs starting in 2027. We have trimmed our longer-term earnings growth forecast to 6% annualized to account for this risk.

The company had delivered a strong series of dividend hikes prior to 2020. However, the dividend was paused during the pandemic before hikes resumed in 2022. The much better earnings performance over the past two years opens the door to larger dividend hikes going forward. In May 2025, the company increased its dividend by 5% to 64 cents per quarter.

¹ In millions.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



National HealthCare Corp. (NHC)

Updated August 14th, 2025, by Ian Bezek

Valuation Analysis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	Now	2030
Avg. P/E	19.9	19.6	18.6	18.0	18.2	25.3	13.4	26.8	21.4	21.5	18.8	20.0
Avg. Yld.	2.3%	2.7%	2.8%	2.8%	2.6%	3.0%	2.0%	3.7%	3.1%	2.3%	2.4%	2.2%

National HealthCare has generally maintained a P/E ratio in the mid-to-high teens. The company's stock fell over the past few quarters, bringing the valuation back in line with historical averages after reaching a high 20s P/E ratio earlier in 2024. We expect the P/E ratio to remain around 20x long-term.

The company has traditionally offered a dividend yield between 2.0% and 3.0%. The firm's yield is within that range now.

Safety, Quality, Competitive Advantage, & Recession Resiliency

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
Payout	46%	53%	51%	51%	46%	76%	39%	93%	66%	49%	45%	43%


National HealthCare saw its payout ratio spike in 2022 given the fall in its earnings, but it is back to more sustainable territory now. The pandemic highlighted several risk factors within the skilled healthcare industry that investors previously hadn't focused on. That said, the industry has normally been viewed as a defensive one serving a growing market given America's aging demographics.

In addition, National HealthCare has a pristine balance sheet, holding a significant net cash position even after its recent White Oak acquisition. This gives it additional flexibility to navigate shifts in the industry going forward.

Final Thoughts & Recommendation

National HealthCare has now fully put its pandemic-related disruptions behind it and has returned to solid growth. The firm's White Oak acquisition is also generating significant shareholder value right out of the gate. Furthermore, the company's strong balance sheet is an asset, and the essential nature of its business leads to steady revenues. Shares were dramatically overvalued throughout much of 2024. That said, the stock price has pulled back even as the earnings outlook has improved considerably. These factors have caused NHC stock to settle around fair value, raising our forward outlook to 9.4% annualized total returns. We maintain a hold rating on National HealthCare today.

Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



National HealthCare Corp. (NHC)

Updated August 14th, 2025, by Ian Bezek

Income Statement Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Revenue	907	924	964	980	996	981	1,011	1,074	1,142	1,298
SG&A Exp.	573	589	612	624	633	650	670	727	42	43
D&A Exp.	37	39	43	42	42	42	41	40	42	42
Operating Profit	70	64	59	61	52	50	60	29	57	90
Op. Margin	7.7%	7.0%	6.1%	6.2%	5.2%	5.1%	5.9%	2.7%	5.0%	6.9%
Net Profit	53	51	56	59	68	42	139	22	67	102
Net Margin	5.9%	5.5%	5.8%	6.0%	6.8%	4.3%	13.7%	2.0%	5.9%	7.9%
Free Cash Flow	25	28	62	69	74	181	23	(21)	83	80
Income Tax	32	30	19	16	20	10	11	7	23	34

Balance Sheet Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	1,045	1,087	1,097	1,081	1,287	1,362	1,403	1,275	1,311	1,524
Cash & Equivalents	38	26	59	43	50	147	108	59	107	76
Acc. Receivable	84	83	87	97	93	90	96	100	109	135
Inventories	8	8	7	7	7	9	9	7	7.4	9
Goodwill & Int.	18	18	18	21	21	21	175	175	175	190
Total Liabilities	414	418	393	346	508	564	495	398	400	541
Accounts Payable	20	19	16	20	19	21	22	17	19	25
Long-Term Debt	120	120	100	55	10	-	-	-	-	137
Total Equity	631	670	703	733	779	795	903	874	909	980
LTD/E Ratio	0.19	0.18	0.14	0.08	0.01	-	-	-	-	0.14

Profitability & Per Share Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Assets	5.0%	4.7%	5.1%	5.4%	5.8%	3.2%	10.0%	1.7%	5.2%	7.2%
Return on Equity	8.9%	7.8%	8.2%	8.2%	9.0%	5.3%	16.3%	2.5%	7.5%	10.8%
ROIC	7.1%	6.6%	7.1%	7.4%	8.6%	5.3%	16.2%	2.5%	7.5%	10.0%
Shares Out.	15	16	15	15	15	15	15	15.5	15.4	15.6
Revenue/Share	62.56	60.73	63.34	64.34	64.87	63.81	65.57	69.55	74.24	83.21
FCF/Share	1.72	1.86	4.08	4.51	4.80	11.80	1.49	(1.39)	5.42	5.11

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.